Traditional MedicareCoverageHigh impact
MolDX: Molecular Testing for Solid Organ Allograft Rejection
Medicare/CMS - LCD·Transplant Surgery, Nephrology, Cardiothoracic Surgery·Local Coverage Determination
We identified it
Sep 3, 2026
Summary
This policy (L38671) for molecular testing in solid organ allograft rejection has been RETIRED as of 8/29/2026. This is a critical update: the policy is no longer active and no longer provides coverage guidance. Billing teams must immediately stop using this policy as a basis for claims and identify the current replacement policy from Noridian Healthcare Solutions to ensure continued compliance.
Action Required
IMMEDIATELY: Billing team must cease using retired policy L38671 (MolDX molecular testing for solid organ allograft rejection) as justification for any claims. Contact Noridian Healthcare Solutions (MAC Part A and Part B contractor) to identify the current active policy that replaces this retired guidance. Audit all claims submitted on or after 8/29/2026 that referenced this policy and determine if resubmission under updated policy guidelines is required. Update billing software and compliance documentation to reflect that L38671 is no longer valid. Failure to identify and implement the replacement policy may result in claim denials and compliance violations.